MapLight Therapeutics (MPLT) Net Income towards Common Stockholders (2024 - 2025)

MapLight Therapeutics (MPLT) reported Net Income towards Common Stockholders of -$81.2 million for Q4 2025, down 276.34% on a YoY basis from $46.1 million in Q4 2024, and down 138.36% sequentially from -$34.1 million in Q3 2025.

MapLight Therapeutics (MPLT) Net Income towards Common Stockholders (2024 - 2025) Analysis & Trends

MapLight Therapeutics (MPLT) has 2 years of Net Income towards Common Stockholders data on file, last reported at -$81.2 million in Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 276.34% year-over-year to -$81.2 million; the trailing twelve-month figure through Dec 2025 stood at -$157.0 million (changed N/A YoY), and the FY2025 full-year result was -$176.2 million, down 93.77% from the prior year.
  • Net Income towards Common Stockholders retreated to -$81.2 million in Q4 2025, from -$34.1 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$20.1 million in Q3 2024 to a low of -$81.2 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -625.73
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -0.68
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 366.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -453.82 Mn
10 MapLight Therapeutics 314.07 Mn 314.07 Mn - -81.21 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -81.21 Mn
Sep 30, 2025 -34.07 Mn
Dec 31, 2024 -21.58 Mn
Sep 30, 2024 -20.11 Mn